Uridine: study protocols
6 study groups say how much Uridine participants took a day. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research
6 study groups in 5 studies say how much Uridine participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 500 mg to 1 g, 33% of 6 study groups.
| Daily dose | Study groups |
|---|---|
| 25 mg or less | 1 |
| 25 mg to 50 mg | 0 |
| 50 mg to 100 mg | 0 |
| 100 mg to 250 mg | 1 |
| 250 mg to 500 mg | 1 |
| 500 mg to 1 g | 2 |
| 1 g to 2.5 g | 0 |
| 2.5 g to 5 g | 0 |
| 5 g to 10 g | 0 |
| 10 g to 25 g | 0 |
| 25 g to 50 g | 0 |
| 50 g to 100 g | 0 |
| over 100 g | 1 |
Commonly used together
4 of 6 study groups took Uridine with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Vitamin B12 | 4 |
6 study groups
| Study | |||
|---|---|---|---|
| Preliminary effects of oral uridine on the ocular surface in dry eye patients 2009 · oral uridine group · Patients aged 13–76 years with moderate-to-severe bilateral dry eye syndrome; mean age 55 years | 150 mg | 90 days | 15 |
| Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial 2007 · uridine group · patients with HIV-associated lipoatrophy receiving unchanged HAART | 108 g | 90 days | — |
| [Effect of the Nucleus CMP forte in 46 patients with progressive spastic paraparesis. Randomized and blind study] 1996 · Nucleus CMP forte · Adults aged 25–79 with idiopathic or HTLV-1-associated progressive spastic paraparesis | 9 mg | 26 weeks | 22 |
| Evaluation of the Efficacy of the Addition of a Combination of Pyrimidine Nucleotides and Vitamin B1 and B12 to Standard Treatment in the Management of Painful Radiculopathy and in the Quality of Life of Patients 2024 · experimental treatment group · Adults aged 18–85 of both sexes with painful radiculopathy of any etiology, upper neuropathic pain, and pain VAS ≥60 mm | 300 mg | 8 weeks | 63 |
| Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease 2015 · Active group (RCT1, RCT2 and RCT3) · Men and women aged 50 years or older with mild or mild-to-moderate Alzheimer's disease; RCT3 participants were on stable approved Alzheimer's medication, while RCT1 and RCT2 participants were drug-free for Alzheimer's medication. | 625 mg | 24 weeks | 501 |
| Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease 2015 · Active product during open-label extension (OLE) · Men and women aged 50 years or older with mild Alzheimer's disease who completed RCT2. | 625 mg | 24 weeks | 201 |